Metformin may have dual effect in breast cancer

Metformin may have dual effect in breast cancer

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects are observed according to homeostasis model assessment (HOMA), particularly in luminal B tumors, according to a study published online May 7 in the Journal of Clinical Oncology.

Bernardo Bonanni, M.D., of the European Institute of Oncology in Milan, and colleagues conducted a randomized trial involving 200 women without diabetes and with operable early-stage who were given either metformin or placebo. The authors sought to investigate the effect of metformin given before surgery on Ki-67.

The researchers found that metformin did not significantly affect Ki-67 compared with placebo. However, in women with HOMA index of greater than 2.8, Ki-67 decreased nonsignificantly, by 10.5 percent, compared with a nonsignificant increase of 11.1 percent in those with HOMA index of 2.8 or lower. In luminal B tumors, metformin had a different effect according to HOMA index (Pinteraction = 0.05). Drug effect modification was demonstrated, with similar trends seen for , waist/hip girth-ratio, , and C-reactive protein.

"In conclusion, our results suggest a heterogeneous effect of metformin on breast cancer proliferation depending on insulin resistance and other factors reflecting altered energy balance, with a trend to a decreased proliferation in women with elevated HOMA index and an opposite trend in women with normal insulin sensitivity," the authors write.

The metformin and placebo used in the study were donated by Laboratori Guidotti in Pisa, Italy.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Metformin appeared to slow prostate cancer growth

Apr 01, 2012

The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Metformin may prevent lung cancer in smokers

Apr 19, 2010

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.